Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on October 14, 2025
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a …
EyePoint Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …
WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq
Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and …
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main …
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that …
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data demonstrates that vorolanib, the active drug …
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …
Oral GLP-1 Tablets Gain Momentum as Telehealth Platform MEDVi Expands Access to Compounded Semaglutide and Tirzepatide for Physician-Supervised Weight Management
Los Angeles, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting any prescription medication or weight-loss program. …
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker
- In combinatie met FOLFOX/FOLFIRI (1L en 2L mCRC) en als monotherapie (3L+ mCRC) toont petosemtamab werkzaamheid tegen tumoren en een beheerbaar veiligheidsprofiel aan UTRECHT, Nederland en CAMBRIDGE, Massachusetts, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Merus …
EmblemHealth Achieves 4-Star Medicare Rating, Highlighting Sustained Quality Improvements
Defying national trends in downward Medicare Advantage ratings for not-for-profit health plans, EmblemHealth increased its Medicare Star rating for the second consecutive year. NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, one of the nation’s …
Breakthrough in Obesity Solutions: Fuzzle’s Non-Invasive Oral Device Begins FDA Review Process
Dover, DE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- In a major step forward for obesity solutions, Fuzzle, a pioneering health technology company, announced today that its innovative oral device has officially entered the U.S. Food and Drug Administration (FDA) …
Lymphoma Antibody Drug Conjugates Treatment Market FDA Approved Drugs Clinical Trials Lymphoma ADC Market Opportunity Insight
Delhi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Global Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales and Clinical Trials Insight 2030 Report Finding …
Nova Leap Health Corp. to Highlight Record Q2 2025 Results at Planet MicroCap Showcase Toronto
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Oct. 14, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is …
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
New York, USA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The melanoma market is expected to witness sustained growth driven by continuous …
The Global Myeloma Community Mourns the Passing of IMF Co-Founder Dr. Brian G.M. Durie
LOS ANGELES, Oct. 14, 2025 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie, co-founder of the organization. A Media Snippet accompanying this announcement is …